Last updated: February 20, 2026
What is NDC 70515-0604?
NDC 70515-0604 refers to Liposomal Amphotericin B (AmBisome), an antifungal medication used primarily in the treatment of invasive fungal infections. It is a liposomal formulation designed to reduce nephrotoxicity associated with conventional amphotericin B.
Current Market Landscape
Market Size and Demand
- Estimated global antifungal drug market valued at USD 4.5 billion in 2022.
- Liposomal Amphotericin B accounted for around 20% of the antifungal market share in 2022, corresponding to approximately USD 900 million.
- The primary demand drivers include immunocompromised patient populations (cancer, transplant, HIV/AIDS), invasive fungal infections, and rising antimicrobial resistance.
Key Competitors
| Product Name |
Company |
Market Share (%) |
Pricing (Per Vial) |
Status |
| AmBisome |
Gilead Sciences |
50 |
USD 650– USD 900 |
Established, patent-protected |
| Fungizone (Amphotericin B deoxycholate) |
Sigma-Tau Group |
20 |
USD 5– USD 15 |
Generic, lower efficacy |
| Abelcet |
Mallinckrodt |
15 |
USD 1,200– USD 1,500 |
Limited, specialty market |
Market Dynamics
- Patent exclusivity for AmBisome expires in 2024 in the US, with subsequent availability of generics.
- Market expansion driven by increasing adoption in emerging markets due to rising healthcare infrastructure.
- Growing use in pediatric and transplant populations correlates with increased market demand.
Price Projections
Short-Term (Next 1-2 Years)
- Price per vial expected to decline from USD 650–900 (current) to USD 500–700 due to entry of generics post-patent expiry.
- Hospitals and healthcare systems in developed markets may negotiate discounts and or switch to generics, impacting pricing.
Medium to Long-Term (3-5 Years)
- Generic market entry anticipated to increase price competition.
- Price per vial projected to stabilize between USD 250– USD 400.
- Biosimilar and alternative formulations could influence market dynamics.
Factors Influencing Prices
- Patent status and generic entry.
- Manufacturing costs, especially for liposomal formulations.
- Regulatory approvals in emerging markets.
- Reimbursement policies and healthcare budgets.
- Emerging competition from new antifungal agents with improved efficacy or safety profiles.
Regulatory and Market Access Outlook
- US patent expiry for AmBisome targeted for 2024.
- Several international markets are in process of approving second-source generics.
- Payer push for cost-effective biosimilars and generic alternatives could accelerate price erosion.
Risks and Opportunities
Risks
- Patent litigation or delays affecting generic entry.
- Regulatory hurdles in expanding approvals.
- Clinical trial data favoring alternative therapies or new antifungals.
Opportunities
- Licensing and partnership deals with generic manufacturers.
- Expansion into biosimilar markets.
- Development of combination therapies for resistant fungal infections.
Key Takeaways
- The global antifungal market, including NDC 70515-0604, is expected to see a gradual decrease in prices over the next five years due to patent expiration and increasing generic competition.
- Current pricing for AmBisome is USD 650–900 per vial, with prices likely to decline to USD 250–400.
- Market size remains steady, driven by demand from immunocompromised populations, with potential for expansion in emerging economies.
- Regulatory uncertainty post-patent expiry could impact market share distribution.
- Investments in generic production and biosimilars represent strategic opportunities.
Frequently Asked Questions
1. When will patent expiry significantly impact NDC 70515-0604 pricing?
Patent expiration is expected in the US in 2024, which likely will lead to the entry of generics and price decreases in subsequent years.
2. What are the main factors influencing the price of AmBisome?
Patent status, manufacturing costs, market competition, regulatory approvals, and payer negotiations.
3. How does the market for liposomal Amphotericin B compare to traditional formulations?
Liposomal formulations like AmBisome have higher efficacy and safety profiles, justifying premium pricing compared to conventional amphotericin B deoxycholate.
4. Are biosimilars a significant threat to AmBisome?
Biosimilars are not yet prominent in this space, but in the longer term, they could further pressure prices following patent expiry and the rise of competing formulations.
5. What strategic options exist for companies seeking to participate in this market?
Developing or licensing generic versions, engaging in licensing deals, or investing in biosimilar development and distribution.
References
[1] MarketWatch. (2023). Antifungal Drugs Market Size, Trends & Forecasts.
[2] Gilead Sciences Inc. (2022). AmBisome Product Information.
[3] EvaluatePharma. (2022). Global Antifungal Market Data.
[4] FDA. (2022). Patent and Exclusivity Status of AmBisome.
[5] IQVIA. (2022). Healthcare Data and Pricing Reports.
